By David Moadel
Publication Date: 2026-06-03 16:22:00
Quick Read
-
NVIDIA and Eli Lilly’s $1 billion AI drug discovery partnership makes both stocks the primary public vehicles for programmable biology exposure.
-
Jeff Bezos reportedly committed $3 billion to longevity startup Altos Labs, while Brian Armstrong’s NewLimit tripled in value to $3 billion.
-
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today.
Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity. According to a Polymarket post on X, Coinbase (NASDAQ:COIN) founder Brian Armstrong’s longevity startup NewLimit has tripled in value to $3.1 billion. That post sparked a viral reply thread from podcast host Mgoes (@m_goes_distance), cataloging billionaire and corporate bets on programmable biology.
For enterprising investors, the hook is simple. When visionary billionaires and blue-chip operators converge on the same theme, it’s worth understanding what they see. Most named startups are privately held, leaving NVIDIA (NASDAQ:NVDA) and Eli Lilly (NYSE:LLY) as the two realistic public-market entry points.
The Verified Anchor: NVIDIA’s $1 Billion Bet With Eli Lilly
In January, NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab, committing up to $1 billion over five years to industrialize drug discovery, with the lab based in the San Francisco Bay Area and…
